Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: “Targeting the Tumor and Tumor Microenvironment” DOI Open Access

Mohd Haseeb,

Imran Khan,

Zeynep Kartal

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11271 - 11271

Published: Oct. 19, 2024

Glioblastoma is the most aggressive and fatal brain cancer, characterized by a high growth rate, invasiveness, treatment resistance. The presence of blood-brain barrier (BBB) tumor (BBTB) poses challenging task for chemotherapeutics, resulting in low efficacy, bioavailability, increased dose-associated side effects. Despite rigorous strategies, including surgical resection, radiotherapy, adjuvant chemotherapy with temozolomide, overall survival remains poor. failure current chemotherapeutics other regimens glioblastoma necessitates development new drug delivery methodologies to precisely efficiently target glioblastoma. Nanoparticle-based systems offer better therapeutic option glioblastoma, considering their small size, ease diffusion, ability cross BBB. Liposomes are specific category nanoparticles made up fatty acids. Furthermore, liposomes can be surface-modified particular receptor nontoxic. This review discusses various methods liposome modification active/directed targeting liposome-based approaches chemotherapeutic drugs nucleic acids microenvironment.

Language: Английский

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions DOI Creative Commons
Justin Tang, Nishika Karbhari, Jian L. Campian

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(7), P. 494 - 494

Published: March 26, 2025

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth, invasive infiltration into surrounding tissue, and resistance to conventional therapies. Despite advancements surgery, radiotherapy, chemotherapy, median survival remains approximately 15 months, underscoring urgent need for innovative treatments. Key considerations informing treatment development include oncogenic genetic epigenetic alterations that may dually serve as therapeutic targets facilitate resistance. Various immunotherapeutic strategies have been explored continue be refined their anti-tumor potential. Technical aspects of drug delivery blood–brain barrier (BBB) penetration addressed through novel vehicles techniques including incorporation nanotechnology. Molecular profiling has emerged an important tool individualize where applicable, identify patient populations with sensitivity. The goal this review describe spectrum potential GBM targets, provide overview key trial outcomes. Altogether, progress clinical preclinical work must critically evaluated order develop therapies strongest efficacy.

Language: Английский

Citations

0
Quality by design enabled development & in-vitro assessment of a Nanoemulgel formulation for Nose-to-Brain delivery of Nintedanib for glioblastoma multiforme treatment DOI
Dnyandev Gadhave, Mural Quadros,

Surendra K. Ravula

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125632 - 125632

Published: April 1, 2025

Language: Английский

Citations

0
Exploring miRNA therapies and gut microbiome–enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting DOI

K. Sandhanam,

Tamilanban Thamaraikani,

Bedanta Bhattacharjee

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 9, 2024

Language: Английский

Citations

2
Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: “Targeting the Tumor and Tumor Microenvironment” DOI Open Access

Mohd Haseeb,

Imran Khan,

Zeynep Kartal

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11271 - 11271

Published: Oct. 19, 2024

Glioblastoma is the most aggressive and fatal brain cancer, characterized by a high growth rate, invasiveness, treatment resistance. The presence of blood-brain barrier (BBB) tumor (BBTB) poses challenging task for chemotherapeutics, resulting in low efficacy, bioavailability, increased dose-associated side effects. Despite rigorous strategies, including surgical resection, radiotherapy, adjuvant chemotherapy with temozolomide, overall survival remains poor. failure current chemotherapeutics other regimens glioblastoma necessitates development new drug delivery methodologies to precisely efficiently target glioblastoma. Nanoparticle-based systems offer better therapeutic option glioblastoma, considering their small size, ease diffusion, ability cross BBB. Liposomes are specific category nanoparticles made up fatty acids. Furthermore, liposomes can be surface-modified particular receptor nontoxic. This review discusses various methods liposome modification active/directed targeting liposome-based approaches chemotherapeutic drugs nucleic acids microenvironment.

Language: Английский

Citations

2